All In Biotech

Drug Trial Radar · NCT02395172

Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)

A Phase III Open-Label, Multicenter Trial of Avelumab (MSB0010718C) Versus Docetaxel in Subjects With Non-Small Cell Lung Cancer That Has Progressed After a Platinum-Containing Doublet

Last checked: Nov 20, 2026Latest source record: Aug 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 792 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

792

Actual

Start

Mar 24, 2015

Primary completion

Nov 22, 2017

Study completion Dec 3, 2019

Sponsor

Sponsor type
Industry
Collaborators
Merck KGaA, Darmstadt, Germany
First posted
Mar 20, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study was to demonstrate superiority with regard to overall survival of avelumab versus docetaxel in participants with programmed death ligand 1 (PD-L1) positive, non-small cell lung cancer (NSCLC) after failure of a platinum-based doublet.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

  • AvelumabDrug

    Participants received 10 milligrams per kilogram (mg/kg) of avelumab as a 1-hour intravenous infusion once every 2 weeks until confirmed disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or Investigational Medicinal Product (IMP) as defined in the study protocol was fulfilled.

  • DocetaxelDrug

    Participants received 75 mg per square meter (m\^2) (per label) of docetaxel by intravenous infusion once every 3 weeks until confirmed disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or Investigational Medicinal Product (IMP) as defined in the study protocol was fulfilled.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS) Time in Programmed Death Ligand 1 (PD-L1) + Full Analysis Set Population (FAS)Time frame: Time from date of randomization up to 1420 days

Locations

260 sites in 29 countries. Site status is shown where the registry gives one.

  • University of Alabama

    Tuscaloosa, Alabama

  • Mayo Clinic

    Scottsdale , Phoenix, Arizona

  • Pacific Cancer Medical Center, Inc.

    Anaheim, California

  • Healing Hands Oncology and Medical Care

    Lawndale, California

  • Sutter Gould Medical Foundation

    Modesto, California

  • Sharp Memorial Hospital

    San Diego, California

  • Lynn Cancer Institute Center

    Boca Raton, Florida

  • University Cancer Institute

    Boynton Beach, Florida

  • Holy Cross Hospital Inc.

    Fort Lauderdale, Florida

  • Florida Cancer Specialists-Broadway

    Fort Myers, Florida

  • Florida Cancer Specialists

    St. Petersburg, Florida

  • Florida Cancer Specialists

    West Palm Beach, Florida

  • Northeast Georgia Cancer Care, LLC

    Athens, Georgia

  • Metairie Oncologist, LLC

    Metairie, Louisiana

  • Henry Ford Health System

    Detroit, Michigan

  • Hematology Oncology Associates of Rockland

    Nyack, New York

  • Novant Health Oncology Specialists

    Winston-Salem, North Carolina

  • Oncology Hematology Care

    Cincinnati, Ohio

  • Signal Point Clinical Research Center

    Middletown, Ohio

  • Mercy Clinic Oklahoma Communities, Inc.

    Oklahoma City, Oklahoma

  • Abington Memorial Hospital

    Abington, Pennsylvania

  • Penn State Univ. Milton S. Hershey Medical Center

    Hershey, Pennsylvania

  • Center for Biomedical Research, LLC

    Knoxville, Tennessee

  • SCRI - Tennessee Oncology

    Nashville, Tennessee

  • The Center for Cancer and Blood Disorders

    Fort Worth, Texas

  • University of Texas Health Science Center at Tyler

    Tyler, Texas

  • MultiCare Health System

    Tacoma, Washington

  • Hospital Italiano Regional del Sur

    Bahía Blanca, Argentina

  • Clínica Universitaria Privada Reina Fabiola

    Barrio General Paz, Argentina

  • Centro de Oncologia e Investigacion Buenos Aires

    Berazategui, Argentina

  • Instituto Medico Especializado Alexander Fleming

    Ciudad Autonoma Buenos Aires, Argentina

  • CEMIC

    Ciudad Autonoma Buenos Aires, Argentina

  • Instituto DAMIC Fundacion Rusculleda

    Córdoba, Argentina

  • Centro Oncologico Riojano Integral (Cori)

    La Rioja, Argentina

  • Centro Oncologico de Parana

    Paraná, Argentina

  • Hospital Universitario Austral

    Pilar, Argentina

  • Instituto Gamma

    Rosario, Argentina

  • Sanatorio Parque S.A.

    Rosario, Argentina

  • Instituto de Oncología de Rosario

    Rosario, Argentina

  • Centro Medico San Roque S.R.L.

    San Miguel de Tucumán, Argentina

Showing 40 of 260 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.